Addex considers out-licensing late preclinical pain candidate
This article was originally published in Scrip
Executive Summary
Addex Pharmaceuticals expects to move its analgesic candidate ADX71943 into clinical testing in the fourth quarter of this year. The Swiss firm is considering out-licensing the product but could initiate clinical testing without a partner.